Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.
Susan C. Modesitt, MD, FACS, FACOG
Advertisement
Articles by Susan C. Modesitt, MD, FACS, FACOG
Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.
Advertisement
Latest Updated Articles
Dr Modesitt on Shared Decision-Making When Choosing PARP Inhibitors in Ovarian CancerPublished: February 29th 2024 | Updated:
Inheritance Matters: The Race to Prevent New Ovarian Cancer CasesPublished: January 31st 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5